

Kenneth Dickstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6286522/publications.pdf>

Version: 2024-02-01

158
papers

12,100
citations

76031

42
h-index

30277

107
g-index

165
all docs

165
docs citations

165
times ranked

12305
citing authors

#	ARTICLE	IF	CITATIONS
1	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€“ a call for action for referral and optimization of care. <i>Europace</i> , 2023, 25, .	0.7	2
2	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. <i>Cardiovascular Research</i> , 2022, 118, 1964-1977.	1.8	10
3	A global perspective of racial differences and outcomes in patients presenting with acute heart failure. <i>American Heart Journal</i> , 2022, 243, 11-14.	1.2	2
4	Additional burden of iron deficiency in heart failure patients beyond the cardioâ€™renal anaemia syndrome: findings from the <sc>BIOSTATâ€™CHF</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 192-204.	2.9	20
5	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <sc>REPORTâ€™CHF</sc> registry. <i>European Journal of Heart Failure</i> , 2022, 24, 645-652.	2.9	18
6	The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. <i>Journal of Women's Health</i> , 2022, 31, 310-320.	1.5	2
7	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	1.5	10
8	Biomarker changes as surrogate endpoints in earlyâ€™phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	1.4	4
9	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327.	1.6	5
10	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 2224-2234.	1.0	22
11	Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from <sc>REPORTâ€™CHF</sc> (International Registry to assess <sc>mEdical</sc> Practice with) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Failure. 2022, . . .	2.9	12
12	Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population.. <i>Turk Kardiyoloji Dernegi Arsivi</i> , 2022, 50, 182-191.	0.2	1
13	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the <sc>SilHF</sc> study): a randomized placeboâ€™controlled multicentre trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1239-1248.	2.9	16
14	Distinct pathophysiological pathways in women and men with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1532-1544.	2.9	10
15	Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 2131-2139.	2.9	8
16	Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. <i>Diabetes Care</i> , 2022, 45, 2152-2155.	4.3	3
17	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , 2021, 117, 2228-2236.	1.8	8
18	Effects of exergaming on exercise capacity inâ€™patients with heart failure: results of an international multicentre randomized controlled trial. <i>European Journal of Heart Failure</i> , 2021, 23, 114-124.	2.9	38

#	ARTICLE	IF	CITATIONS
19	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	2.9	19
20	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 555-567.	2.9	15
21	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021, 23, 567-577.	2.9	26
22	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 349-359.	1.9	14
23	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	0.7	18
24	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021, 44, 780-788.	0.7	3
25	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective) <i>Tj ETQq1 1 0.7843149gBT /Overlock 10</i>	1.4	10
26	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3168-3179.	1.4	33
27	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021, 110, 1334-1349.	1.5	4
28	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.	1.2	3
29	Impact of mitral regurgitation in patients with worsening heart failure: insights from <scp>BIOSTAT-CHF</scp>. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	2.9	32
30	Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 127-131.	0.4	3
31	128â€fClinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
32	Benchmarking Belgian CRT practice against the rest of Europe: insights from the ESC-CRT survey II. <i>Acta Cardiologica</i> , 2020, 75, 492-496.	0.3	0
33	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	2.9	28
34	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	2.9	50
35	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	2.9	15
36	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 401.	3.0	51

#	ARTICLE	IF	CITATIONS
37	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1402-1411.	2.9	19
38	Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II. <i>Clinical Research in Cardiology</i> , 2020, 109, 832-844.	1.5	3
39	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 528-538.	2.9	28
40	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-HF study. <i>European Journal of Heart Failure</i> , 2020, 22, 81-89.	2.9	15
41	Implications of serial measurements of natriuretic peptides in heart failure: insights from <scp>BIOSTAT-HF</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1486-1490.	2.9	7
42	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020, 22, 2370-2379.	2.9	14
43	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	2.9	101
44	Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 634-640.	0.6	1
45	Remote monitoring of cardiac implanted electronic devices: legal requirements and ethical principles - ESC Regulatory Affairs Committee/EHRA joint task force report. <i>Europace</i> , 2020, 22, 1742-1758.	0.7	32
46	A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. <i>Nutrients</i> , 2020, 12, 2541.	1.7	16
47	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020, 22, 1133-1143.	2.9	16
48	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. <i>ESC Heart Failure</i> , 2020, 7, 953-963.	1.4	9
49	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. <i>The Lancet Global Health</i> , 2020, 8, e411-e422.	2.9	104
50	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 234-242.	1.9	25
51	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. <i>European Journal of Heart Failure</i> , 2020, 22, 848-855.	2.9	14
52	CRT Survey II: a European Society of Cardiology (ESC) survey of cardiac resynchronization therapy—an Irish subset analysis. <i>Irish Journal of Medical Science</i> , 2020, 189, 895-905.	0.8	0
53	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	3.0	59
54	The prevalence and importance of frailty in heart failure with reduced ejection fraction—An analysis of <scp>PARADIGM-HF</scp> and <scp>ATMOSPHERE</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 2123-2133.	2.9	85

#	ARTICLE	IF	CITATIONS
55	Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. <i>Europace</i> , 2020, 22, 932-938.	0.7	8
56	Cardiac resynchronization therapy in Romania “ results from the European Society of Cardiology CRT Survey II. <i>Revista Romana De Cardiologie</i> , 2020, 30, 48-55.	0.0	1
57	Current clinical practice of cardiac resynchronization therapy in Turkey: reflections from CRT SURVEY-II. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 382-396.	0.5	1
58	Second European Cardiac Resynchronisation Therapy Survey (Crt Survey Ii): Latvian Data Compared to Europe. <i>Proceedings of the Latvian Academy of Sciences</i> , 2020, 74, 358-365.	0.0	0
59	The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 713-722.	0.7	0
60	Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1248-1258.	2.9	21
61	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019, 394, 1254-1263.	6.3	159
62	Sex-Related Procedural Aspects and Complications in CRT Survey II. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1048-1058.	1.3	12
63	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 696.	3.0	43
64	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>American Heart Journal</i> , 2019, 215, 83-90.	1.2	7
65	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	2.9	172
66	Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. <i>Lancet, The</i> , 2019, 393, 1045-1055.	6.3	48
67	Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 1020-1030.	0.4	0
68	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , 2019, 108, 1215-1225.	1.5	17
69	Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?“ findings from the ESC CRT Survey II. <i>Europace</i> , 2019, 21, 918-927.	0.7	19
70	Income Inequality and Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.	1.9	63
71	Contemporary practice of CRT implantation in scandinavia compared to Europe. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 9-13.	0.4	1
72	Cardiac resynchronization in Poland “ comparable procedural routines? Insights from CRT Survey II. <i>Postepy W Kardiologii Interwencyjnej</i> , 2019, 15, 477-484.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019, 73, 29-40.	1.2	168
74	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 112-120.	2.9	44
75	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019, 21, 577-587.	2.9	38
76	Effectiveness of the European Society of Cardiology/Heart Failure Association website "heartfailurematters.org" and an e-health adjusted care pathway in patients with stable heart failure: results of the "e-Vita HF" randomized controlled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 238-246.	2.9	56
77	Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 231-241.	0.4	22
78	Do we differ in terms of indications and demographics in cardiac resynchronisation recipients in Poland? Insights from the European CRT Survey II Registry. <i>Kardiologia Polska</i> , 2019, 77, 40-46.	0.3	2
79	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients "who is doing what to whom and how?". <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	2.9	107
80	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	2.9	93
81	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction) Tj ETQq1 1 0.7843047rgBT /Overlock		
82	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 727-735.	1.2	28
83	Guideline recommendations for cardiac resynchronization therapy evolve but does clinical practice match the pace?. <i>European Journal of Heart Failure</i> , 2018, 20, 778-779.	2.9	0
84	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	1.2	35
85	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2018, 20, 323-331.	2.9	23
86	Indications for Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2018, 6, 308-316.	1.9	68
87	Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1325-1333.	1.2	14
88	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <scp>ATMOSPHERE</scp> trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147.	2.9	18
89	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	1.1	6
90	Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure. <i>International Journal of Cardiology</i> , 2018, 271, 181-185.	0.8	14

#	ARTICLE	IF	CITATIONS
91	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	0.8	140
92	Upgrades from a previous device compared to <i>de novo</i> cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. <i>European Journal of Heart Failure</i> , 2018, 20, 1457-1468.	2.9	44
93	Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure. <i>Journal of Hypertension</i> , 2018, 36, 1736-1742.	0.3	10
94	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2018, 272, 260-266.	0.8	24
95	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	1.2	199
96	Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	20
97	Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. <i>Swiss Medical Weekly</i> , 2018, 148, w14643.	0.8	1
98	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. <i>European Heart Journal</i> , 2017, 38, ehw506.	1.0	22
99	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	2.9	183
100	A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. <i>European Journal of Heart Failure</i> , 2017, 19, 635-642.	2.9	24
101	Early clinical benefit after cardiac resynchronization therapy: fortunately, QRS width and ejection fraction are still the best predictors. <i>European Journal of Heart Failure</i> , 2017, 19, 1064-1066.	2.9	1
102	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
103	Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. <i>International Journal of Cardiology</i> , 2017, 249, 274-281.	0.8	1
104	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53
105	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	1.2	43
106	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1560-1562.	1.6	15
107	heartfailurematters.org™, an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions. <i>European Journal of Heart Failure</i> , 2017, 19, 1447-1454.	2.9	21
108	Do real world data support and extend our ability to predict reverse remodelling following cardiac resynchronization therapy based on QRS morphology and width?. <i>European Journal of Heart Failure</i> , 2017, 19, 1152-1153.	2.9	1

#	ARTICLE	IF	CITATIONS
109	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.	1.2	114
110	Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2017, 19, 271-279.	2.9	32
111	Rationale for and design of the <sc>TRUE-AHF</sc> trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	2.9	31
112	Heartfailurematters.org. <i>European Heart Journal</i> , 2017, 38, 2861-2862.	1.0	1
113	Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. <i>European Heart Journal</i> , 2017, 38, 2936-2943.	1.0	91
114	Telerehabilitation in heart failure patients: The evidence and the pitfalls. <i>International Journal of Cardiology</i> , 2016, 220, 408-413.	0.8	73
115	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart MicroMics™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , 2016, 14, 181.	2.3	48
116	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	0.7	12
117	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532.	13.9	204
118	Natriuretic peptide levels taken following unplanned admission to a cardiology department predict the duration of hospitalization. <i>European Journal of Heart Failure</i> , 2016, 18, 1499-1505.	2.9	8
119	What constitutes optimal neurohumoral antagonism in chronic heart failure?. <i>Heart</i> , 2016, 102, 1922-1932.	1.2	3
120	Does the presence of mitral regurgitation strengthen or weaken the indication for cardiac resynchronization therapy?. <i>European Journal of Heart Failure</i> , 2016, 18, 1069-1071.	2.9	0
121	A systems Biology Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2016, 18, 716-726.	2.9	149
122	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <small>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</small>	0.7	26
123	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	2.7	1
124	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	1.2	191
125	Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2016, 37, 49-59.	1.0	43
126	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	2.9	315

#	ARTICLE	IF	CITATIONS
127	Predicting outcomes following CRT: the quest continues. <i>European Journal of Heart Failure</i> , 2015, 17, 645-646.	2.9	2
128	The Aliskiren Trial to Minimize <sc>OutcomeS</sc> in Patients with <sc>HEart</sc> failure trial (<sc>ATMOSPHERE</sc>): revised statistical analysis plan and baseline characteristics. <i>European Journal of Heart Failure</i> , 2015, 17, 1075-1083.	2.9	18
129	Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: the rationale, design and methodology of the HF&Wii study; a multicentre randomized controlled trial. <i>European Journal of Heart Failure</i> , 2015, 17, 743-748.	2.9	56
130	Effectiveness of an interactive platform, and the ESC/HFA heartfailurematters.org website in patients with heart failure: design of the multicentre randomized e&Vita heart failure trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1310-1316.	2.9	19
131	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine â€ short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	1.0	105
132	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
133	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High&Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2015, 17, 1144-1151.	2.9	84
134	European Cardiac Resynchronization Therapy Survey II: rationale and design. <i>Europace</i> , 2015, 17, 137-141.	0.7	22
135	The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. <i>International Journal of Cardiology</i> , 2015, 191, 256-264.	0.8	125
136	Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues. <i>European Heart Journal</i> , 2015, 36, 2279-2280.	1.0	4
137	The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2015, 36, 1983-1989.	1.0	65
138	Increased pulmonary vascular resistance, right ventricular dysfunction, and reversible pulmonary vasoconstriction in type 2 pulmonary hypertension: who has it and are we missing a potential therapeutic target in patients with heart failure?. <i>European Journal of Heart Failure</i> , 2015, 17, 237-238.	2.9	2
139	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
140	Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: a randomized trial. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1427-1434.	0.8	40
141	Cardiac myosin activation: will theory and practice coincide?. <i>Lancet, The</i> , 2011, 378, 639-641.	6.3	5
142	Chronic right ventricular pacing, adverse remodelling, and CRT: an ounce of prevention?. <i>European Heart Journal</i> , 2011, 32, 2483-2485.	1.0	4
143	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1143-1153.	2.9	152
144	Response to Coceani: Cardiac Resynchronization Therapy Has Earned Its Class I Recommendation and Continues to Thrive Under Scrutiny. <i>Circulation: Heart Failure</i> , 2010, 3, 556-558.	1.6	0

#	ARTICLE	IF	CITATIONS
145	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>Europace</i> , 2010, 12, 1526-1536.	0.7	297
146	2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Heart Journal</i> , 2010, 31, 2677-2687.	1.0	427
147	The European cardiac resynchronization therapy survey. <i>European Heart Journal</i> , 2009, 30, 2450-2460.	1.0	215
148	Remote monitoring of patients with cardiac failure. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	1
149	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008, 29, 2388-2442.	1.0	2,656
150	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.	2.9	1,893
151	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez. <i>European Journal of Heart Failure</i> , 2007, 9, 1224-1225.	2.9	2
152	The impact of morbid events on survival following hospitalization for complicated myocardial infarction. <i>European Journal of Heart Failure</i> , 2006, 8, 74-80.	2.9	9
153	Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. <i>European Journal of Heart Failure</i> , 2005, 7, 303-308.	2.9	19
154	Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 440-441.	3.3	0
155	Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. <i>American Journal of Cardiology</i> , 2004, 94, 237-239.	0.7	38
156	Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. <i>Lancet</i> , The, 2002, 360, 752-760.	6.3	1,059
157	ELITE II and Val-HeFT are different trials: together what do they tell us?. , 2001, 2, 240.		20
158	Angiotensin II antagonists are superior to ACE inhibitors; David vs. Goliath. <i>European Journal of Heart Failure</i> , 2000, 2, 235-236.	2.9	2